Last update 23 Jan 2025

OPA1 x VEGF x Tubulin

Basic Info

Related Targets
OPA1VEGFTubulin

Related

1
Drugs associated with OPA1 x VEGF x Tubulin
PYC-001
Target
OPA1 x Tubulin x VEGF
Mechanism
OPA1 inhibitors [+2]
Active Org.
PYC Therapeutics Ltd.PYC Therapeutics Ltd.
Originator Org.
PYC Therapeutics Ltd.PYC Therapeutics Ltd.
Active Indication
Optic Atrophy, Autosomal Dominant
Inactive Indication
Diabetic Retinopathy
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with OPA1 x VEGF x Tubulin
NCT06461286
/ RecruitingPhase 1
A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
100 Clinical Results associated with OPA1 x VEGF x Tubulin
Login to view more data
100 Translational Medicine associated with OPA1 x VEGF x Tubulin
Login to view more data
0 Patents (Medical) associated with OPA1 x VEGF x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free